![Page 1: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/1.jpg)
Office of In Vitro Diagnostic Device Evaluation and Safety
Donald St.PierreDeputy Director for New Device Evaluation
AdvaMed’s 13th Annual Device Submissions Workshop
![Page 2: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/2.jpg)
The Story Line
Organization & Resources Workload Review Statistics MDUFMA
![Page 3: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/3.jpg)
I. ORGANIZATION &RESOURCES
![Page 4: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/4.jpg)
Structure - OIVD
Single Organizational Unit Premarket Compliance Post-market One Stop Shopping Delayered – no more branches Streamlined – minimal administrative support
![Page 5: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/5.jpg)
OIVD (con’t)
Goals Increased TransparencyUniform Least Burdensome ApproachExpedited Technology Transfer Improve Connectivity and Quality of Work
Objective - TPLC Common Technical Base Faster Response Time
![Page 6: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/6.jpg)
SEE ORGANIZATIONAL CHART
![Page 7: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/7.jpg)
Thanks to MDUFMA Approaching FY01 Staffing Level
11th Annual Workshop – 6612th Annual Workshop – 5413th Annual Workshop – 63
Doug Wood (DCTD - 5/18) Cecily Jones (DIHD – 6/1) Marieanne Brill (DMD – 6/1) 3 more are in-process Total Projected --70-75 by EOY
![Page 8: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/8.jpg)
Parallel to other offices ODE
Same commitments, responsibilitiesAdopt spirit of LB, summaries/balance
OCSame commitments, responsibilitiesStill learning, moving 510(k)s this direction, 30-
day notice changes, tracking, MOU OSB
Eggs in MedSun basketMove from MDRs to active surveillance
![Page 9: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/9.jpg)
Other Offices - Projects
OSTSoftware supportGuidance collaboration
OHIPStill some pt labeling/human factorsOIVD website
OSMCollaborative software, databases,
tracking, eReview
![Page 10: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/10.jpg)
External Outreach IVD Roundtable Professional IVD Roundtable Pharmacogenomic Roundtable Therapeutic Drug Management RT Internal Staff College NIH/NCI CDC/CMS SAMHSA
![Page 11: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/11.jpg)
II. WORKLOAD
![Page 12: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/12.jpg)
PMA Receipts (½ FY03)
Original PMAs 2
Normal PMA/S 8
Panel-Track PMA/S 1
Real-Time PMA/S 12
30-day notice 15
Special PMA/S 9
PMA Modules 8
![Page 13: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/13.jpg)
510(k) Receipts (½ FY03)
All 510(k)s 361
Traditional 315
Abbreviated 14
Special 32
![Page 14: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/14.jpg)
Other OIVD Documents
Pre-IDE Pre-IDE
Supple.
IDE IDE Supple.
FY99 55 10 1 11
FY00 64 11 3 8
FY01 85 16 1 10
FY02 96 33 4 9
½ FY03 39 15 1 0
![Page 15: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/15.jpg)
Other Receipts (½ FY03)
HDE 0
PDP 0
513(g) 9
![Page 16: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/16.jpg)
Standards Activities
5 revised 4 withdrawn 15 new
(See 4/28/03 FR notice)
![Page 17: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/17.jpg)
GHTF CDRH active in all Study Groups (SG); OIVD
active in SG 1 (POC - Ginette Michaud) SG1: operational aspects of medical device
regulation including IVD productsCurrent IVD harmonization projects: classification labeling IVD premarket conformity with principles
for safety and performance STED (?)
![Page 18: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/18.jpg)
FY03 Guidance Documents
Multiplex Tests for Heritable DNA Markers, Mutations and Expression Patterns
Antimicrobial Susceptibility Test (AST) Systems
Analyte Specific Reagents; Small Entity Compliance Guidance
![Page 19: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/19.jpg)
Guidances In-the-Works
Coagulation NIOX and 1 other Denovo Replacement Reagent Glucose IVD Device Studies (BiMo)
![Page 20: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/20.jpg)
OIVD Counter Terrorism Activities
Established emergency response plans, in conjunction with HHS and FDA, to monitor and respond to a terrorist event
Expediting the review of device submissions related to counter terrorism and military need
Evaluating the safety and effectiveness of diagnostic test kits that detect biothreat agents
Participated in TOPOFF Exercise
![Page 21: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/21.jpg)
Other Resource Issues
Classifications – Herpes, B. Anthracis, Yersinia Pestis
Scorecards CBER/CDRH interactions CPI TPLC/Patient Safety SARS/WNV ASRs/Genetics CLIA/OC
![Page 22: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/22.jpg)
On the Web FY03
510(k) - IDI Strep B for Preg. Women 510(k) - pro-BNP for CHF 510(k) - Home Glycated Hemoglobin for
Diabetics 510(k) - Cobalt Albumin to rule out Heart
Attack 510(k) - Breath test for Asthma 510(k) - Aspergillus
![Page 23: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/23.jpg)
On the Web FY03
Lab Safety Tips Accu Chek class II Recall SSED - P020027 (FPSA) SSED - P020011 (HCV) IVD 510(k) Workshop Expanded use for HPV Consumer Information
![Page 24: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/24.jpg)
Ongoing Activities
Performance ScorecardsLooking for measurable outcomes (e.g.,)
Decrease enforcement actions Decrease recalls Decrease MDRs Decrease review times Increase decision quality Improve BiMo audit results Measure feedback
![Page 25: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/25.jpg)
Ongoing Activities
New IVD Webpage (good first effort)www.fda.gov/cdrh/oivd
Standardizing review format Learning about compliance Learning about post-market MedSun to LabSun Post-market safety team
![Page 26: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/26.jpg)
Post-Market Safety Team - Themes
Consumer education/outreach Internal training (522 authority, STAMP,
safety alerts, public health advisories/notifications, MDRs, MedWatch, MedSun)
Tap Epi group – databases/literature Pick a disease and focus Active Surveillance ideas
![Page 27: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/27.jpg)
III. Review Statistics
![Page 28: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/28.jpg)
Original PMA Approvals
# of Decisions
Ave
FDA
Time
Ave
MFG
Time
Ave
Total
Time
FY02 OIVD
ODE
7
41
221
259
45
105
266
364
½ FY03 OIVD
ODE
3
14
216
261
24
143
240
404
![Page 29: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/29.jpg)
PMA Supplement Approvals
# of Decisions
Ave
FDA
Time
Ave
MFG
Time
Ave
Total
Time
FY02 OIVD
ODE
54
532
145
96
19
28
164
124
½ FY03 OIVD
ODE
30
270
81
83
13
31
94
114
![Page 30: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/30.jpg)
½ FY03 510(k) Review Stats n FDA
time
MFG time
Total
time
All 510(k)s OIVD
ODE
354
2164
56
75
13
28
69
103
Trad. OIVD
ODE
312
1643
59
86
14
33
73
119
Abbrev. OIVD
ODE
10
109
48
75
11
20
59
95
Special OIVD
ODE
32
412
26
28
4
8
30
36
![Page 31: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/31.jpg)
510(k) Review Stats
FY02 ½ FY03
Ave # of cycles OIVD
ODE
1.43
1.40
1.31
1.40
Ave # FDA days/cycle OIVD
ODE
45
55
43
53
Ave # MFG days/cycle OIVD
ODE
43
64
40
60
![Page 32: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/32.jpg)
CLIA Workload
0
200400
600800
10001200
14001600
18002000
FY99 FY00 FY01 FY02 FY03
WaivedModerateHigh
![Page 33: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/33.jpg)
IV. MDUFMA
Participating on implementation teams
Providing input on Guidances
Clarifying terminology
Bundling
![Page 34: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/34.jpg)
Bundling Principles
Historically Done – continue Not Historically Done – don’t, unless it
makes sense & can be reviewed efficiently Second thoughts on our part (e.g., HBV) Guidance Coming No fee for Replacement Reagents
![Page 35: Office of In Vitro Diagnostic Device Evaluation and Safety](https://reader036.vdocuments.mx/reader036/viewer/2022062309/56814530550346895db1f77c/html5/thumbnails/35.jpg)
Challenges for the New Millennium
CLIA waiver Genetic Diseases/ASRs Microarrays/High throughput assays Turbo 510(k) TPLC Integrating all the work of the Center
into OIVD